EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sapropterin Dihydrochloride Responsiveness in Phenylketonuria: A Case Series Exploring Gaps in Comprehensive Patient Monitoring

Manuela Lo Bianco iD, Roberta Leonardi iD, Alessia Migliore, Evelina Moliteo iD, Monica Sciacca, Sergio Rinella iD, Maria Grazia Pappalardo, Luisa La Spina, Marianna Messina iD, Riccardo Iacobacci, Martino Ruggieri iD, Concetta Meli und 1 weitere

Nutrients · 2025

DOI: 10.3390/nu17172892 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von Manuela Lo Bianco und 12 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Pediatric Clinic, A.O.U. Policlinico "G. Rodolico-San Marco", P.O. "G. Rodolico"-University of Catania, 95123 Catania, Italy. Hauptthemen laut MEDLINE: Phenylketonurias, Biopterins. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Phenylketonuria (PKU) is a rare autosomal recessive metabolic disorder caused by mutations in the phenylalanine hydroxylase (PAH) gene, leading to hyperphenylalaninemia (HPA). Untreated, elevated phenylalanine (Phe) levels cause severe neurocognitive, developmental, and psychiatric complications. Management relies on a Phe-restricted diet, which is challenging to maintain, particularly in adolescents and adults. Sapropterin dihydrochloride, a synthetic form of tetrahydrobiopterin (BH4), can enhance residual PAH activity, lowering blood Phe levels and increasing dietary tolerance in responsive patients. However, real-world alignment with best practices remains underexplored. This study aims to report a tertiary referral center’s experience with sapropterin treatment in PKU and assess adherence to international guidelines.

Methods

We retrospectively analyzed 23 PKU patients treated with sapropterin from 2007 to 2025. Patients with baseline Phe levels of 360–2000 µmol/L underwent a 10 mg/kg/day loading test over two weeks. Responsiveness was defined as a ≥30% reduction in blood Phe levels. Phe levels were measured pre- and post-test, and dietary tolerance was evaluated. Adherence to best practices was critically reviewed.

Results

All patients showed significant Phe reductions (mean 71.43%, p < 0.0001), exceeding responsiveness thresholds. Most achieved substantial increases in dietary Phe tolerance, with three patients partially responsive (800–1200 mg/day). Responsiveness was unrespectful of the patient’s genotype, for those individuals for whom this was known (8/23 patients). Although effective, the test dose and duration differed from guideline recommendations (20 mg/kg/day). Neuropsychological and QoL assessments were not systematically performed, representing a key limitation.

Conclusions

Sapropterin dihydrochloride effectively identified responders and improved dietary flexibility even with lower dosing protocols. Greater adherence to international standards, particularly regarding long-term neuropsychological monitoring, is needed to optimize patient care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhenylketonuriasBiopterinsHumansMaleFemalePhenylalanineRetrospective StudiesAdolescentAdultChildYoung AdultChild, PreschoolTreatment OutcomePhenylalanine Hydroxylase

Stichwörter der Autor:innen

BH4 loading testinternational best practicephenylalanine hydroxylase (PAH)phenylketonuria (PKU)sapropterin dihydrochloride

Substanzen

BiopterinssapropterinPhenylalaninePhenylalanine Hydroxylase

Autor:innen und Institutionen

  • Unit of Pediatric Clinic, A.O.U. Policlinico "G. Rodolico-San Marco", P.O. "G. Rodolico"-University of Catania, 95123 Catania, Italy.
  • Postgraduate Residency Program in Pediatrics, Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
  • Neonatal Intensive Care Unit (NICU), A.O.U. Policlinico "G. Rodolico-San Marco", P.O. "G. Rodolico"-University of Catania, 95123 Catania, Italy.
  • Unit of Pediatrics, Neonatology and Neonatal Intensive Care (NICU), San Vincenzo Hospital, 98039 Taormina, Italy.
  • Department of Educational Sciences, University of Catania, 95131 Catania, Italy.
  • Unit of Expanded Neonatal Screening and Inherited Metabolic Diseases, Pediatric Clinic, Department of Medical Sciences, University of Catania, 95123 Catania, Italy.

ORCID-Profile: Manuela Lo Bianco, Roberta Leonardi, Evelina Moliteo, Sergio Rinella, Marianna Messina, Martino Ruggieri, Agata Polizzi

Zitieren

APA

Lo Bianco, M., Leonardi, R., Migliore, A., Moliteo, E., Sciacca, M., Rinella, S., Pappalardo, M. G., La Spina, L., Messina, M., Iacobacci, R., Ruggieri, M., Meli, C., & Polizzi, A. (2025). Sapropterin Dihydrochloride Responsiveness in Phenylketonuria: A Case Series Exploring Gaps in Comprehensive Patient Monitoring. Nutrients. https://doi.org/10.3390/nu17172892

Vancouver

Lo Bianco M, Leonardi R, Migliore A, Moliteo E, Sciacca M, Rinella S, et al. Sapropterin Dihydrochloride Responsiveness in Phenylketonuria: A Case Series Exploring Gaps in Comprehensive Patient Monitoring. Nutrients. 2025. doi:10.3390/nu17172892

BibTeX
@article{LoBianco2025,
  author = {Lo Bianco, Manuela and Leonardi, Roberta and Migliore, Alessia and Moliteo, Evelina and Sciacca, Monica and Rinella, Sergio and Pappalardo, Maria Grazia and La Spina, Luisa and Messina, Marianna and Iacobacci, Riccardo and Ruggieri, Martino and Meli, Concetta and Polizzi, Agata},
  title = {Sapropterin Dihydrochloride Responsiveness in Phenylketonuria: A Case Series Exploring Gaps in Comprehensive Patient Monitoring},
  journal = {Nutrients},
  year = {2025},
  doi = {10.3390/nu17172892}
}
Kostenlos starten →